News

Anaplastic Large Cell Lymphoma In Women with Breast Implants: Preliminary FDA Findings & Analyses

Posted Date: January 26, 2011

Reports in the scientific community have suggested a possible association between anaplastic large cell lymphoma (ALCL) and breast implants.

Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses
Executive Summary

Reports in the scientific community have suggested a possible association between anaplastic large cell lymphoma (ALCL) and breast implants. In its January 2011 report, the FDA summarizes the scientific data the Agency used to assess the possible association. It represents the FDA’s current understanding, based on the published scientific literature on ALCL in women with breast implants and information gathered through the FDA’s contact with other regulatory authorities, scientific experts, and breast implant manufacturers. The document includes the FDA’s analyses of the data and steps it plans to take to better understand and characterize the possible association.

The report, Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses, is published on the FDA website

PLEASE ENTER YOUR PORTAL LOGIN


CANCEL